Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
- PMID: 27079802
- PMCID: PMC5381938
- DOI: 10.1038/nrc.2016.36
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Abstract
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.
Conflict of interest statement
The authors declare
Figures
Similar articles
-
Combination cancer immunotherapy and new immunomodulatory targets.Nat Rev Drug Discov. 2015 Aug;14(8):561-84. doi: 10.1038/nrd4591. Nat Rev Drug Discov. 2015. PMID: 26228759 Review.
-
The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Ann Am Thorac Soc. 2017 Aug;14(8):1248-1260. doi: 10.1513/AnnalsATS.201702-152FR. Ann Am Thorac Soc. 2017. PMID: 28613923 Review.
-
Immune checkpoint blockade in lymphoid malignancies.FEBS J. 2016 Jun;283(12):2233-44. doi: 10.1111/febs.13668. Epub 2016 Feb 22. FEBS J. 2016. PMID: 26807978 Review.
-
Immune checkpoint therapy for non-small-cell lung cancer: an update.Immunotherapy. 2016;8(3):279-98. doi: 10.2217/imt.15.123. Epub 2016 Feb 9. Immunotherapy. 2016. PMID: 26860624 Review.
-
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009. Epub 2015 Jul 17. Clin Cancer Res. 2015. PMID: 26187615 Free PMC article.
Cited by
-
Novel tumor gene expression signatures improve the overall survival prediction efficiency over tumor mutation burden and PD-L1 expression in bladder carcinoma with checkpoint blockade immunotherapy.Am J Cancer Res. 2024 Sep 15;14(9):4411-4428. doi: 10.62347/TIMD7591. eCollection 2024. Am J Cancer Res. 2024. PMID: 39417183 Free PMC article.
-
STARD7 could be an immunological and prognostic biomarker: from pan-cancer analysis to hepatocellular carcinoma validation.Discov Oncol. 2024 Oct 10;15(1):543. doi: 10.1007/s12672-024-01434-x. Discov Oncol. 2024. PMID: 39390226 Free PMC article.
-
Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens.J Biomed Sci. 2024 Oct 9;31(1):94. doi: 10.1186/s12929-024-01082-x. J Biomed Sci. 2024. PMID: 39379923 Free PMC article. Review.
-
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.Nat Med. 2024 Sep 30. doi: 10.1038/s41591-024-03240-y. Online ahead of print. Nat Med. 2024. PMID: 39349627
-
Boosting immunotherapy efficacy: Empowering the Potency of Dendritic cells loaded with breast cancer lysates through CTLA-4 suppression.Heliyon. 2024 Sep 10;10(18):e37699. doi: 10.1016/j.heliyon.2024.e37699. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39309891 Free PMC article.
References
-
- Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials